Vitamin D receptor is a novel drug target for ovarian cancer treatment

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Ovarian cancer is a leading cause of gynecological cancer death in the US, with current treatments having poor outcomes.
• Epidemiological data suggest a link between higher latitude, vitamin D insufficiency, and increased ovarian cancer incidence and mortality.
• Ovarian cancer cell lines demonstrate sensitivity to the active form of vitamin D, 1alpha,25-dihydroxyvitamin D(3), for growth inhibition.

Purpose of the Study:

• To investigate the anti-tumor effects of vitamin D and its analogs on ovarian cancer.
• To elucidate the molecular mechanisms underlying vitamin D-induced growth suppression and apoptosis in ovarian cancer cells.
• To evaluate the therapeutic potential of vitamin D analogs in preclinical ovarian tumor models.

Main Methods:

• Treatment of ovarian cancer cell lines with 1alpha,25-dihydroxyvitamin D(3) and assessment of cell growth, cell cycle, and apoptosis.
• Identification and analysis of vitamin D-regulated genes involved in ovarian tumorigenesis, including p27 and GADD45.
• Evaluation of the synthetic vitamin D analog EB1089 in human ovarian tumor xenografts in mice, assessing tumor growth, apoptosis, and proliferation.

Main Results:

• 1alpha,25-dihydroxyvitamin D(3) suppressed ovarian cancer cell growth by inducing cell cycle arrest at G1/S and G2/M checkpoints via p27 stabilization and GADD45 upregulation.
• Vitamin D treatment led to apoptosis in ovarian cancer cells through down-regulation of telomerase catalytic subunit mRNA stability.
• The synthetic vitamin D analog EB1089 significantly suppressed human ovarian tumor xenograft growth in mice, associated with increased apoptosis and decreased proliferation.

Conclusions:

• The vitamin D receptor mediates anti-tumor effects in ovarian cancer, representing a novel therapeutic target.
• Vitamin D analogs demonstrate potential for ovarian tumor suppression, translating molecular findings into preclinical efficacy.
• Receptor-based drug discovery targeting the vitamin D receptor may lead to more potent and safer vitamin D analogs for ovarian cancer treatment.